Abstract CT233: A phase 2b study of subcutaneous amivantamab with lazertinib as first-line treatment, or with chemotherapy as second-line treatment, for EGFR-mutated non-small cell lung cancer (NSCLC): COPERNICUS
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Balazs Halmos, Narjust Florez, Sarah Goldberg, Wade Iams, Xiuning Le, Ticiana Leal, Danny Nguyen, Luis E. Raez, Jonathan W. Riess, Joshua Sabari, David Bjork, Nichelle Stigger, Yichuan Xia, Paul Cifuentes, Denise D’Andrea, Andy L. Johnson, Melissa L. Johnson
Institutions: Albert Einstein College of Medicine, Montefiore Medical Center, Harvard University, Dana-Farber Cancer Institute, Yale University, Tennessee Oncology, The University of Texas MD Anderson Cancer Center, Emory University, Winship Cancer Institute, UC Davis Comprehensive Cancer Center, NYU Langone Health, New York University, LUNGevity Foundation, Johnson & Johnson (United States), Sarah Cannon
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409821812